Select a Region

North America

Newscenter

Browsing Archive: HTAHTA | EVERSANA

Posted on 4 月 11, 20254/11/25

Unlocking Pharma Success: Mike Ryan’s Pre-Conference Talk at Reuters Pharma 2025

Posted on 4 月 10, 20254/10/25

Unlock the Power of Indirect Treatment Comparisons (ITC) with Industry Experts

Posted on 2 月 27, 20252/27/25

Securing Launch Success Within the Context of the New EU Health Technology Assessment Regulation (HTAR) Landscape in Europe

Posted on 7 月 11, 20247/11/24

Key Insights from ARCS 2024: Shaping the Future of HTA and Reimbursement in Australia

Posted on 3 月 27, 20243/27/24

Growing EVERSANA’s Value & Evidence Global Footprint with the Additions of Monique Martin, Pamela Vo and Deepika Thakur

Posted on 10 月 23, 202310/23/23

Adapting to Change: Examining the Implications of New EU Regulations on Commercialisation from the Perspectives of Patients, Providers, and Pharma Companies

Posted on 10 月 17, 202310/17/23

Utilization of Indirect Treatment Comparison (ITC), External Control Arms (ECA) and Patient-Reported Outcome Measures (PROMs)

Posted on 8 月 1, 20238/1/23

Commercial Key Success Factors (KSFs) for Global Drug Development Programs

Posted on 4 月 17, 20234/17/23

What EVERSANA’s Growing Abstract Count at ISPOR U.S. Means to the HEOR Industry

Posted on 10 月 12, 202210/12/22

The Evolution of HTA and Its Impact on Drug Prices in Japan

HTA